Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

WIN Consortium—challenges and advances

Nature Reviews Clinical Oncology volume 8, pages 133–134 (2011)Cite this article

Subjects

The importance of appropriate patient selection necessitates novel clinical trial design and biomarker-driven trials to allow delivery of the right drug to the right patient at the right time—personalized cancer medicine. The WIN Consortium promotes collaboration between critical stakeholders and offers diverse populations of cancer patients the opportunity to participate in clinical trials with new drugs and biologics that target their tumor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kim, E. S. et al. The BATTLE Trial (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination): Personalizing therapy for lung cancer. Proceedings of American Association of Cancer Research (Late Breaking Abstracts-1) (2010).

  2. Wistuba, I. I. et al. Methodological and practical challenges for personalized cancer therapies. Nat. Rev. Clin. Oncol. 8, 135–141 (2011).

    Article  CAS  Google Scholar 

  3. Bang, Y. et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 28 (18 Suppl.), a3 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030, TX, USA

    John Mendelsohn

  2. Department of Medical Oncology and INSERM U981, Comprehensive Cancer Center, University of Chicago, 5801 South Ellis Avenue, Chicago, 60637, IL, USA

    Thomas Tursz

  3. Institut Genomic Unit, Comprehensive Cancer Center, University of Chicago, 5801 South Ellis Avenue, Chicago, 60637, IL, USA

    Vladimir Lazar

  4. Institut de Cancérologie, Gustave Roussy, 39 Rue Camille Desmoulins, Villejuif, 94805, France

    Richard L. Schilsky

  5. Department of Medicine, Section of Hematology–Oncology, Comprehensive Cancer Center, University of Chicago, 5801 South Ellis Avenue, Chicago, 60637, IL, USA

    Richard L. Schilsky

Authors
  1. John Mendelsohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Tursz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard L. Schilsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vladimir Lazar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Mendelsohn.

Ethics declarations

Competing interests

Dr. Richard L. Schilsky declares he is a consultant for Foundation Medicine. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mendelsohn, J., Tursz, T., Schilsky, R. et al. WIN Consortium—challenges and advances. Nat Rev Clin Oncol 8, 133–134 (2011). https://doi.org/10.1038/nrclinonc.2010.230

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.230

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing